<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00798070</url>
  </required_header>
  <id_info>
    <org_study_id>PANTHER SBG2004-1</org_study_id>
    <secondary_id>2007-002061-12</secondary_id>
    <secondary_id>ISRCTN39017665</secondary_id>
    <secondary_id>ABCSG25</secondary_id>
    <secondary_id>GBG53</secondary_id>
    <nct_id>NCT00798070</nct_id>
  </id_info>
  <brief_title>Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients</brief_title>
  <acronym>PANTHER</acronym>
  <official_title>PANTHER. A Randomized Phase 3 Study Comparing Biweekly and Tailored Epirubicin + Cyclophosphamide Followed by Biweekly Tailored Docetaxel (dtEC→dtT) Versus Three Weekly Epirubicin + Cyclophosphamide + 5-fluorouracil Followed by Docetaxel (FEC→T) in Lymph Node Positive or High Risk Lymph Node Negative Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swedish Breast Cancer Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Austrian Breast &amp; Colorectal Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Breast Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an adjuvant, open, prospective, randomized study to compare:

      A. Individually tailored and two weekly dosed epirubicin + cyclophosphamide followed by a
      three weeks break followed by biweekly and tailored docetaxel (dtEC→dtT) given every second
      week, to

      B. Fixed dosed and three weekly epirubicin, cyclophosphamide and 5-fluorouracil, followed by
      fixed dosed and three weekly docetaxel (FEC→T).

      Patients with primary node-positive or high risk lymph node negative breast cancer will be
      eligible for the study.

      The primary objective of the phase 3 study is to compare breast cancer relapse-free survival
      (BCRFS) between the dtEC→dtT and FE100C→T. To detect a five-year BCRFS difference of 0.710 to
      0.790 about 1000 patients per arm will be needed. They will be recruited during four years
      and followed another two years for breast cancer events.

      Secondary objectives are to compare

        1. Distant disease-free survival (DDFS)

        2. Event-free survival and

        3. Overall survival

        4. Health-related quality of life and toxicity analyses according to CTC

        5. Outcome in relation to tumour biological factors and polymorphism patterns

             1. RFS in relation to the Sorlie classes using immunohistochemical markers and/or gene
                expression profiling comparing A vs B arm

             2. RFS with receptor positive disease (analyzed in the local laboratories as described
                in the CRFs and also analyzed as continuous variables) in the comparison between
                the A- and B- arms.

             3. RFS with high and low proliferation, respectively, (analyzed in the local
                laboratories as described in the CRFs and also analyzed as a continuous variable,
                or centrally analyzed), in the comparison between the A- and B-arms.

             4. RFS in relation to HER-2/neu status (analyzed in the local laboratories as
                described in the CRFs) in the primary cancers in the comparison between the A- and
                B-arms and analyzed whether trastuzumab was given in sequence or concurrently.

             5. RFS analyzed in relation to other molecular markers (e.g. gene expression
                profiling/ sequencing) in the primary cancers and SNPs signatures in normal DNA
                (related to toxicities for EC/FEC and docetaxel components, respectively, and given
                dose levels and outcome in relation to these factors and in relation QoL) to
                outcome per arm.

             6. RFS analyzed in relation to tumour associated lymphocytes and Y-box binding protein
                in the comparison between the A- and B-arms.

      Tumour tissue will be obtained and stored for studies of prognostication and therapy
      prediction.

      Last patient randomized was September 2011.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Are described under the heading &quot;Outcome measures&quot;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Breast cancer relapse-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Breast cancer recurrence free survival is defined as time from randomization to the first of the events; local-, regional- or distant breast cancer recurrence or death due to breast cancer or last date of follow-up if no event has occurred. This was defined already in the phase 2 protocol (1 Sept 2004).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distant disease-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Distant disease free survival is defined as time from randomization to the first of distant metastases or death due to breast cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Event-free survival is defined as time from randomization to the first of the events breast cancer recurrence (any type), contra-lateral breast cancer, other malignancy or any cause of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival is defined as time from randomization to any death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life and toxicity analyses according to CTC</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome in relation to tumour biological factors and polymorphism patterns</measure>
    <time_frame>2 years</time_frame>
    <description>Comparing arm A vs B regarding:
RFS in relation to the Sorlie classes using immunohistochemical markers and/or gene expression profiling comparing A vs B arm;
RFS with receptor positive disease in the comparison between the A- and B arms;
RFS with high and low proliferation, respectively, in the comparison between the A- and B-arms.;
RFS in relation to HER-2/neu status in the primary cancers in the comparison between the A- and B-arms and analyzed whether trastuzumab was given in sequence or concurrently;
RFS analyzed in relation to other molecular markers in the primary cancers and SNPs signatures in normal DNA to outcome per arm;
RFS analyzed in relation to tumour associated lymphocytes and Y-box binding protein in the comparison between the A- and B-arms.
Description of a to e are more detailed in the protocol, shortened here due to space limitation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BCRFS in arm A in relation to given dose levels</measure>
    <time_frame>2 years</time_frame>
    <description>Breast cancer relapse free survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2017</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: dtEC→dtT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individually tailored and two weekly dosed epirubicin + cyclophosphamide followed by a three weeks break followed by biweekly and tailored docetaxel (dtEC→dtT) given every second week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: FEC→T</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fixed dosed and three weekly epirubicin, cyclophosphamide and 5-fluorouracil, followed by fixed dosed and three weekly docetaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dtEC→dtT</intervention_name>
    <description>Individually tailored and two weekly dosed epirubicin (start dose 90mg/m2) + cyclophosphamide (start dose 600mg/m2) followed by a three weeks break followed by biweekly and tailored docetaxel (start dose 75mg/m2) given every second week. If toxicity measured by CTC-NCI criteria are grade 2 or less (except haematological toxicity) it will be possible to escalate doses</description>
    <arm_group_label>Arm A: dtEC→dtT</arm_group_label>
    <other_name>Epirubicin</other_name>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FEC→T</intervention_name>
    <description>Fixed dosed and three weekly epirubicin (100mg/m2), cyclophosphamide (500mg/m2) and 5-fluorouracil (500mg/m2), followed by fixed dosed and three weekly docetaxel (100mg/m2), no dose escalations.</description>
    <arm_group_label>Arm B: FEC→T</arm_group_label>
    <other_name>Epirubicin</other_name>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Fluorouracil</other_name>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological proven invasive primary breast cancer, with at least 5 (recommended 10)
             removed axillary lymph nodes OR negative sentinel node biopsy performed for the node
             negative cohort. Interval between definitive surgery that includes axillary lymph node
             dissection and registration must be less than 60 days. Paraffin block from the primary
             tumour must be retained (not mandatory for Austrian sites). Frozen tumour tissue is
             strongly recommended to be stored.

          -  Receptor negative or positive tumours with 1 or more positive axillary lymph nodes
             (more than 0.2 mm) OR axillary node negative breast cancers if the primary tumour is
             larger than 20 mm and receptor negative (Er and Pgr with no receptor content) and
             being Elston grade III. In Germany high risk node negative breast cancer patients are
             not eligible until labelling for docetaxel includes node-negative disease.

          -  A primary breast cancer patient being 35 years or younger considered suitable for
             adjuvant chemotherapy (may be receptor negative or positive, HER-2/neu negative or
             positive, with or without axillary lymph node metastases).

          -  Macroscopically and microscopically free margins after radical surgery (no cancer
             cells at borders of resection).

          -  No proven distant metastases (negative chest/pulmonary X-ray, bone scintigram (when
             clinical signs of skeletal metastases or elevated ALP) supplemented with normal
             conventional X-ray of hot spots, normal liver function test and haematological
             function tests; when abnormal values, CT or ultrasound of the liver, patient can be
             included if no metastases are demonstrated.

          -  Female age 18-65.

          -  Ambulant patients (ECOG 1 or less).

          -  No major cardiovascular morbidity NYHA I or II. (Appendix 3).

          -  Written informed consent according to the local ethics committee requirements.

          -  Patients of childbearing potential should have a negative pregnancy test within seven
             days of registration. (In Austria, pregnancy tests have to be repeated monthly during
             the treatment phase).

        Exclusion Criteria:

          -  Previous neo-adjuvant treatment.

          -  Non-radical surgery (histopathological positive margins).

          -  Proven distant metastases.

          -  Pregnancy or lactation.

          -  Other serious medical condition.

          -  Previous or concurrent malignancies at other sites, except basal cell carcinoma and/or
             squamous cell carcinoma in situ of the skin or cervix. Patients with previous breast
             cancer (invasive and/or ductal carcinoma in situ) in the other breast without
             loco-regional (large lung volumes) radiotherapy, without objective findings for
             relapse, with &gt; 5 years since diagnosis can be included.

          -  Abnormal laboratory values precluding the possibility to safely deliver the used
             cytotoxic agents in the study.

          -  Hypersensitivity to drugs formulated in polysorbate 80.

          -  Peripheral neuropathy grade ≥2.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonas Bergh, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MUG - Med. Univ.-Klinik Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUI - Univ. Klinik f. Frauenheilkunde, Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LKH Leoben</name>
      <address>
        <city>Leoben</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH Linz</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KH BHS Linz</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LKH Rankweil</name>
      <address>
        <city>Rankweil</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LKH Salzburg / PMU</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KH BHB St. Veit/Glan</name>
      <address>
        <city>St. Veit/Glan</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels - Grieskirchen GmbH</name>
      <address>
        <city>Wels</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brustzentrum Hanusch-KH</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhospital</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum am Bruderwald</name>
      <address>
        <city>Bamberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bayreuth</name>
      <address>
        <city>Bayreuth</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bietigheim</name>
      <address>
        <city>Bietigheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Sindelfingen-Böblingen</name>
      <address>
        <city>Boblingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johanniter Krankenhaus</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Celle</name>
      <address>
        <city>Celle</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Deggendorf</name>
      <address>
        <city>Deggendorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonissen Krankenhaus</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus St. Joseph-Stift</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Adhami</name>
      <address>
        <city>Erkelenz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der J. W. Goethe Universität</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt Höchst GmbH</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Gemeinschaftspraxis</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kreiskrankenhaus</name>
      <address>
        <city>Freudenstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Fulda</name>
      <address>
        <city>Fulda</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Goslar</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus St. Elisabeth und St. Barbara</name>
      <address>
        <city>Halle an der Saale</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik</name>
      <address>
        <city>Halle an der Saale</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Hameln</name>
      <address>
        <city>Hameln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henriettenstiftung</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Heilbronn</name>
      <address>
        <city>Heilbronn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemienschaftspraxis</name>
      <address>
        <city>Hildesheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik</name>
      <address>
        <city>Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincentius Kliniken</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elisabeth Krankenhaus</name>
      <address>
        <city>Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Kempten</name>
      <address>
        <city>Kempten</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth-KKH</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincenz Krankenhaus</name>
      <address>
        <city>Limburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Tagesklinik</name>
      <address>
        <city>Lohsa</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigsburg</name>
      <address>
        <city>Ludwigsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ev. Krankenhaus</name>
      <address>
        <city>Ludwigsfelde</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincenz und Elisabeth-Hospital</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Fichtelgebirge</name>
      <address>
        <city>Marktredwitz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Praxis</name>
      <address>
        <city>Memmingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis am Klinikum Neumarkt</name>
      <address>
        <city>Neumarkt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Praxis</name>
      <address>
        <city>Pinneberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum am Steinenberg</name>
      <address>
        <city>Reutlingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rheinfelden</name>
      <address>
        <city>Rheinfelden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Schwerin</name>
      <address>
        <city>Schwerin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gesellschaft für onkologische Studien</name>
      <address>
        <city>Troisdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Tuttlingen</name>
      <address>
        <city>Tuttlingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Villingen-Schwenningen</name>
      <address>
        <city>Villingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Weiden</name>
      <address>
        <city>Weiden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Weinheim</name>
      <address>
        <city>Weinheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Paulinen Klinik</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Josefs-Hospital</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stadtkrankenhaus</name>
      <address>
        <city>Worms</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Hospital</name>
      <address>
        <city>Gävle</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Hospital</name>
      <address>
        <city>Karlstad</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malmö General University Hospital</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital, Dept of Oncology</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Hospital</name>
      <address>
        <city>Sundsvall</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norrlands University Hospital</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala Academic Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.kpeks.se/sbg20041</url>
    <description>Swedish website for the study</description>
  </link>
  <results_reference>
    <citation>Foukakis T, von Minckwitz G, Bengtsson NO, Brandberg Y, Wallberg B, Fornander T, Mlineritsch B, Schmatloch S, Singer CF, Steger G, Egle D, Karlsson E, Carlsson L, Loibl S, Untch M, Hellström M, Johansson H, Anderson H, Malmström P, Gnant M, Greil R, Möbus V, Bergh J; Swedish Breast Cancer Group (SweBCG), the German Breast Group (GBG), and the Austrian Breast &amp; Colorectal Cancer Study Group (ABCSG). Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial. JAMA. 2016 Nov 8;316(18):1888-1896. doi: 10.1001/jama.2016.15865.</citation>
    <PMID>27825007</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2008</study_first_submitted>
  <study_first_submitted_qc>November 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2008</study_first_posted>
  <last_update_submitted>November 16, 2016</last_update_submitted>
  <last_update_submitted_qc>November 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Prof Jonas Bergh</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Lymph node positive or high risk lymph node negative breast</keyword>
  <keyword>cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Oral presentation at ASCO 4 June 2016 (completed). Study published in JAMA 8 Nov 2016.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

